Gilead Sciences (NASDAQ:GILD): $10.23 million was the positive money flow into the stock on Wednesday and the up/down ratio of ticks was also in favor of the bulls at 1.07. The value of trades done on upticks was $155.78 million, whereas, trades done on downticks were valued at $145.56 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $20.95 million worth stocks on upticks, which is a bullish indication. The downticks accounted only for $2.84 million worth of block trades showing a lack of interest among the large traders to sell the stock down. The up/down ratio of 7.38 was strongly in favor of the bulls. The money flow in block trades was $18.11 million. Gilead Sciences (NASDAQ:GILD) fell $0.04 traded at $82.27, a change of -0.05% over the previous day. The stock is 2.24% for the week.
In an insider trading activity, The director officer (President and CEO), of Gilead Sciences Inc, Milligan John F had unloaded 112,000 shares at $86.92 per share in a transaction on June 6, 2016. The total value of transaction was $9,735,040. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 1.4% of Gilead Sciences shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.9% . Institutional Investors own 81.78% of Gilead Sciences shares. During last six month period, the net percent change held by insiders has seen a change of -9.29%.
The company shares have dropped -29.05% from its 1 Year high price. On Aug 4, 2015, the shares registered one year high at $120.37 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $84.12 and the 200 Day Moving Average price is recorded at $90.78. Gilead Sciences (NASDAQ:GILD): The stock opened at $83.39 on Wednesday but the bulls could not build on the opening and the stock topped out at $83.46 for the day. The stock traded down to $81.75 during the day, due to lack of any buying support eventually closed down at $82.27 with a loss of -0.05% for the day. The stock had closed at $82.31 on the previous day. The total traded volume was 10,452,557 shares.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.